Impact of Morphine Treatment on Platelet Inhibition in Acute Myocardial Infarction

• Status: Completed
• Trial end date: 2018-10-01
• Target enrollment: 0
• Participant gender: All

Summary

The current prospective, randomized, controlled MonAMI trial aims to systematically examine the effects of morphine on the platelet inhibitory effects of the orally administered platelet inhibitor ticagrelor in patients with acute myocardial infarction. In addition, the potential positive or negative effects of MCP in combination with morphine on platelet inhibition will be studied.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Luebeck
• Treatments: Metoclopramide; Morphine; Ticagrelor

Criteria

Inclusion Criteria:

1. ST-elevation myocardial infarction < 24 h after symptom onset or non-ST-elevation myocardial infarction with persistent chest pain < 24 h after symptom onset

2. Intended revascularization by primary percutaneous coronary intervention

3. Informed consent

4. Age ≥18 years

Exclusion Criteria:

1. Age <18 years

2. Active bleeding or bleeding diathesis

3. Oral anticoagulation

4. Current treatment with clopidogrel/prasugrel/ticagrelor/glycoprotein-IIb-IIIa-receptor-antagonists

5. Current treatment with morphine and/or MCP <12 h

6. Contraindication for treatment with platelet inhibitors

7. Fibrinolysis <48 h

8. Percutaneous coronary intervention or coronary artery bypass grafting <3 months

9. Known glomerular filtration rate <30 ml/min

10. Severe liver dysfunction

11. Hypersensitivity to ticagrelor or any excipients

12. History of intracranial hemorrhage

13. Known pregnancy, breast-feeding or intend to become pregnant during the study period

14. Participation in other trial